Discovery Labs Receives New US Patent for Pulmonary Surfactant Formulations

Discovery Labs Receives New US Patent for Pulmonary Surfactant Formulations

WARRINGTON, Pa., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Discovery Laboratories,
Inc. (Nasdaq:DSCO) today announced it has received a patent issued by the
United States Patent and Trademark Office (USPTO) entitled "Pulmonary
Surfactant Formulations." The claims of the patent (U.S. Patent Number
8,337,815) provide coverage for synthetic pulmonary surfactant compositions
comprising a combination of a proprietary synthetic peptide and various
lipids. The patent term expires in December 2028.

"The Company's strategy is to seek broad patent protection in the field of
synthetic surfactants," said John G. Cooper, President and Chief Executive
Officer at Discovery Labs. "This patent, together with our existing KL4
formulation patents covering SURFAXIN^® and combinations of pulmonary
surfactant with protease inhibitors, as well as our patents covering methods
of use and manufacture, provides a strong foundation for our continued
leadership in the development of synthetic surfactants."

This patent provides exclusivity for new formulations of KL4 surfactant and is
separate and distinct from the patent portfolios covering SURFAXIN, the
Company's lead KL4 surfactant product, and AEROSURF^®, the Company's lead KL4
surfactant development program.

Discovery Laboratories, Inc. is a specialty biotechnology company with one
focus – to advance a new standard in respiratory critical care. Discovery
Labs' novel proprietary KL4 surfactant technology produces a synthetic,
peptide-containing surfactant that is structurally similar to pulmonary
surfactant and is being developed in liquid, lyophilized, and aerosolized
dosage forms. Discovery Labs is also developing its proprietary drug delivery
technologies to enable efficient delivery of aerosolized KL4 surfactant and
other inhaled therapies. Discovery Labs believes that its proprietary
technologies make it possible, for the first time, to develop a significant
pipeline of products to address a variety of respiratory diseases for which
there frequently are few or no approved therapies.

Discovery Labs' strategy is initially focused on the development of its
technologies to improve the management of respiratory distress syndrome (RDS)
in premature infants. Discovery Labs believes that its RDS product portfolio
has the potential to become the new standard of care for RDS and, over time,
to significantly expand the current worldwide RDS market.

For more information, please visit our website at

Forward-Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from the
statements made. Examples of such risks and uncertainties are described in
Discovery Labs' filings with the Securities and Exchange Commission, including
the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments
thereto. Any forward-looking statement in this release speaks only as of the
date on which it is made. Discovery Labs assumes no obligation to update or
revise any forward-looking statements.

CONTACT: Media Relations:
         Michael Parks, Pitch360 - 484.356.7105
         Investor Relations:
         Michael Rice, LifeSci Advisors - 646.597.6979
         John Tattory, Vice President of Finance,
         Discovery Labs - 215.488.9418

Discovery Labs Logo
Press spacebar to pause and continue. Press esc to stop.